COVID-19 and Health Outcomes in People with Multiple Sclerosis: A Population-Based Study in Italy

被引:0
|
作者
Gnavi, Roberto [1 ]
Eboli, Ilenia [1 ]
Alboini, Paolo Emilio [2 ]
D'Alfonso, Sandra [3 ,4 ]
Picariello, Roberta [1 ]
Costa, Giuseppe [1 ,5 ]
Leone, Maurizio [2 ]
机构
[1] ASL TO3 Reg Piemonte, Epidemiol Unit, I-10095 Grugliasco, Italy
[2] Fdn IRCCS Casa Sollievo della Sofferenza, Neurol Unit, I-71013 San Giovanni Rotondo, Italy
[3] Univ Piemonte Orientale, Dept Hlth Sci, I-28100 Novara, Italy
[4] Univ Piemonte Orientale, CAAD, I-28100 Novara, Italy
[5] Univ Turin, Dept Biol & Clin Sci, I-10128 Turin, Italy
来源
LIFE-BASEL | 2023年 / 13卷 / 05期
关键词
multiple sclerosis; COVID-19; outcome assessment; health care;
D O I
10.3390/life13051089
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
People with multiple sclerosis (PWMS) are at high risk of being affected by the disruption of health services that occurred during the COVID-19 pandemic months. The aim of this study was to evaluate the effect of the pandemic on the health outcomes of PWMS. PWMS and MS-free residing in Piedmont (north-west of Italy) were identified from electronic health records and linked with the regional COVID-19 database, the hospital-discharge database, and the population registry. Both cohorts (9333 PWMS and 4,145,856 MS-free persons) were followed-up for access to swab testing, hospitalisation, access to the Intensive Care Unit (ICU), and death from 22 February 2020 to 30 April 2021. The relationship between the outcomes and MS was evaluated using a logistic model, which was adjusted for potential confounders. The rate of swab testing was higher in PWMS, but the positivity to infection was similar to that of MS-free subjects. PWMS had a higher risk of hospitalisation (OR = 1.74; 95% IC, 1.41-2.14), admission to ICU (OR = 1.79; 95% IC, 1.17-2.72), and a slight, albeit not statistically significant, increase in mortality (OR = 1.28; 95% IC, 0.79-2.06). Compared to the general population PWMS with COVID-19 had an increased risk of hospitalization and admission to the ICU; the mortality rate did not differ.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study
    Affinito, Giuseppina
    Trama, Ugo
    Palumbo, Laura
    Fumo, Maria Grazia
    Giordana, Roberta
    Di Gennaro, Massimo
    Triassi, Maria
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Palladino, Raffaele
    Moccia, Marcello
    NEUROLOGICAL SCIENCES, 2023, 44 (11) : 3771 - 3779
  • [2] Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study
    Giuseppina Affinito
    Ugo Trama
    Laura Palumbo
    Maria Grazia Fumo
    Roberta Giordana
    Massimo Di Gennaro
    Maria Triassi
    Roberta Lanzillo
    Vincenzo Brescia Morra
    Raffaele Palladino
    Marcello Moccia
    Neurological Sciences, 2023, 44 : 3771 - 3779
  • [3] Multiple sclerosis is associated with worse COVID-19 outcomes compared to the general population: A population-based study
    Barzegar, Mahdi
    Sindarreh, Setayesh
    Manteghinejad, Amirreza
    Mirmosayyeb, Omid
    Mazaheri, Shahrbanoo
    Rahimi, Maryam
    Javanmard, Shaghayegh Haghjooy
    Shaygannejad, Vahid
    Nasirian, Maryam
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [4] COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population
    Mayer, Dijana
    Barun, Barbara
    Lazibat, Karla
    Lasic, Slava
    Adamec, Ivan
    Gabelic, Tereza
    Skoric, Magdalena Krbot
    Habek, Mario
    ACTA NEUROLOGICA BELGICA, 2023, 123 (06) : 2269 - 2275
  • [5] COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population
    Dijana Mayer
    Barbara Barun
    Karla Lazibat
    Slava Lasić
    Ivan Adamec
    Tereza Gabelić
    Magdalena Krbot Skorić
    Mario Habek
    Acta Neurologica Belgica, 2023, 123 : 2269 - 2275
  • [6] Mental Health Status of People with Multiple Sclerosis during the COVID-19 Pandemic
    Wilski, Maciej
    Koper, Magdalena
    Gabryelski, Jaroslaw
    Brola, Waldemar
    Tasiemski, Tomasz
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (03)
  • [7] Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study
    Rodriguez-Fernandez, Almudena
    Visos-Varela, Irene
    Zapata-Cachafeiro, Maruxa
    Pintos-Rodriguez, Samuel
    Garcia-Alvarez, Rosa M.
    Herdeiro, Teresa M.
    Pineiro-Lamas, Maria
    Figueiras, Adolfo
    Salgado-Barreira, Angel
    INFLAMMOPHARMACOLOGY, 2024, 32 (04) : 2305 - 2315
  • [8] Risk and outcomes of COVID-19 in patients with multiple sclerosis
    Moreno-Torres, Irene
    Meca Lallana, Virginia
    Costa-Frossard, Lucienne
    Oreja-Guevara, Celia
    Aguirre, Clara
    Alba Suarez, Elda Maria
    Gomez Moreno, Mayra
    Borrega Canelo, Laura
    Sabin Munoz, Julia
    Aladro, Yolanda
    Carcamo, Alba
    Rodriguez Garcia, Elena
    Cuello, Juan Pablo
    Monreal, Enric
    Sainz de la Maza, Susana
    Perez Parra, Fernando
    Valenzuela Rojas, Francisco
    Lopez de Silanes de Miguel, Carlos
    Casanova, Ignacio
    Martinez Gines, Maria Luisa
    Blasco, Rosario
    Orviz Garcia, Aida
    Villar-Guimerans, Luisa Maria
    Fernandez-Dono, Guillermo
    Elvira, Victor
    Santiuste, Carmen
    Espino, Mercedes
    Garcia Dominguez, Jose Manuel
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (11) : 3712 - 3721
  • [9] Strategy to reduce adverse health outcomes in subjects highly vulnerable to COVID-19: results from a population-based study in Northern Italy
    Russo, Antonio Giampiero
    Faccini, Marino
    Bergamaschi, Walter
    Riussi, Antonio
    BMJ OPEN, 2021, 11 (03):
  • [10] COVID-19 in ocrelizumab-treated people with multiple sclerosis
    Hughes, Richard
    Whitley, Louise
    Fitovski, Kocho
    Schneble, Hans-Martin
    Muros, Erwan
    Sauter, Annette
    Craveiro, Licinio
    Dillon, Paul
    Bonati, Ulrike
    Jessop, Nikki
    Pedotti, Rosetta
    Koendgen, Harold
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49